aHypoxemic structural heart defects potentially detectable through pulse oximetry screening at birth hospitals include critical aortic stenosis, coarctation of the aorta, double-outlet right ventricle, dextrotransposition of the great arteries, Ebstein anomaly, hypoplastic left heart syndrome, pulmonary atresia, interrupted aortic arch, critical pulmonary stenosis, single ventricle, truncus arteriosus, total anomalous pulmonary venous return, tetralogy of Fallot, and tricuspid atresia.
eFigure 1. Frequency of late detection among 3746 infants by critical congenital heart disease (CCHD) type and presence of extracardiac defects. From the National Birth Defects Prevention Study, 1998-2007
eFigure 2. Frequency of late detection among infants by critical congenital heart disease (CCHD) type and study site, for defects with >10 infants per study site. From the National Birth Defects Prevention Study, 1998-2007
Peterson C, Ailes E, Riehle-Colarusso T, et al. Late detection of critical congenital heart disease among US infants: estimation of the potential impact of proposed universal screening using pulse oximetry. JAMA Pediatr. Published online February 3, 2014. doi:10.1001/jamapediatrics.2013.4779.
Peterson C, Ailes E, Riehle-Colarusso T, Oster ME, Olney RS, Cassell CH, Fixler DE, Carmichael SL, Shaw GM, Gilboa SM. Late Detection of Critical Congenital Heart Disease Among US InfantsEstimation of the Potential Impact of Proposed Universal Screening Using Pulse Oximetry. JAMA Pediatr. 2014;168(4):361-370. doi:10.1001/jamapediatrics.2013.4779
Critical congenital heart disease (CCHD) was added to the Recommended Uniform Screening Panel for Newborns in the United States in 2011. Many states have recently adopted or are considering requirements for universal CCHD screening through pulse oximetry in birth hospitals. Limited previous research is directly applicable to the question of how many US infants with CCHD might be identified through screening.
To estimate the proportion of US infants with late detection of CCHD (>3 days after birth) based on existing clinical practice and to investigate factors associated with late detection.
Design, Setting, and Participants
Descriptive and multivariable analysis. Data were obtained from a multisite population-based study of birth defects in the United States, the National Birth Defects Prevention Study (NBDPS). We included all live-born infants with estimated dates of delivery from January 1, 1998, through December 31, 2007, and nonsyndromic, clinically verified CCHD conditions potentially detectable through screening via pulse oximetry.
Main Outcomes and Measures
The main outcome measure was the proportion of infants with late detection of CCHD through echocardiography or at autopsy under the assumption that universal screening at birth hospitals might reduce the number of such late diagnoses. Secondary outcome measures included prevalence ratios for associations between selected demographic and clinical factors and late detection of CCHD.
Of 3746 live-born infants with nonsyndromic CCHD, late detection occurred in 1106 (29.5% [95% CI, 28.1%-31.0%]), including 6 (0.2%) (0.1%-0.4%) first receiving a diagnosis at autopsy more than 3 days after birth. Late detection varied by CCHD type from 9 of 120 infants (7.5% [95% CI, 3.5%-13.8%]) with pulmonary atresia to 497 of 801 (62.0% [58.7%-65.4%]) with coarctation of the aorta. In multivariable analysis, late detection varied significantly by CCHD type and study site, and infants with extracardiac defects were significantly less likely to have late detection of CCHD (adjusted prevalence ratio, 0.58 [95% CI, 0.49-0.69]).
Conclusions and Relevance
We estimate that 29.5% of live-born infants with nonsyndromic CCHD in the NBDPS received a diagnosis more than 3 days after birth and therefore might have benefited from routine CCHD screening at birth hospitals. The number of infants in whom CCHD was detected through screening likely varies by several factors, including CCHD type. Additional population-based studies of screening in practice are needed.
Congenital heart defects affect approximately 1% of live births, of which 25% are estimated to be critical and require surgery or catheterization within the first year of life.1 Infants with critical congenital heart defects (also referred to as critical congenital heart disease [CCHD]) who are discharged from birth hospitals without a diagnosis are at risk for cardiovascular collapse and death.1Quiz Ref IDNewborn screening for CCHD through pulse oximetry can detect some CCHD conditions (eg, those who present with hypoxemia [low blood oxygen saturation] shortly after birth) even in the absence of other physical symptoms and thereby avert late detection.2 Screening is recommended at birth hospitals within 24 to 48 hours of birth.3Quiz Ref IDPulse oximetry is a noninvasive test that quantifies hypoxemia. A single reading of less than 90% from a neonate’s hand or foot or the combination of a 90% to 95% single reading and a difference of more than 3% in the readings for the upper and lower extremities is flagged for follow-up.3 In recent clinical studies, pulse oximetry has demonstrated high specificity and moderate sensitivity to detect CCHD and a low false-positive rate.2,4Quiz Ref IDCritical congenital heart disease was added to the US recommended uniform screening panel for newborns in 2011.5 Legislation to require screening was recently adopted or is under consideration in most states (http://www.aap.org/stateadvocacy).6,7
Previous studies have examined issues related to late CCHD detection (defined for our study as >3 days after birth), although few such studies facilitate direct estimates of the impact that universal screening might have in the United States. For example, several potentially relevant US studies were not population based or lacked sufficient follow-up to identify infants with missed CCHD after discharge from the birth hospital.8- 13 Studies from European countries and elsewhere in the world are illuminating, but not directly applicable to the US clinical context.14- 27 The most relevant US population-based studies of late detection of CCHD published before the federal recommendation for routine screening through pulse oximetry produced widely varied estimates—ranging from 4.3% to 31.3%—of infants with CCHD who received late diagnoses (Table 1).29- 33,35 The substantial variability of those estimates appears to result from differences in case definition, data sources, length of follow-up, study size, and exclusive use of administrative coding to identify CCHD diagnoses. Administrative diagnostic codes may inaccurately classify some heart defects; for example, the severity of aortic or pulmonary stenosis can determine whether such conditions can be detected by screening, although such severity is not distinguished through administrative codes.36,37 Moreover, those studies did not examine late detection in a manner suited to estimate the potential effect of universal screening; for example, some studies examined only missed diagnoses resulting in infant death33,35 or did not examine the full range of CCHD conditions that screening might detect.29- 33 At least 2 studies28,34 have examined the population-based effect of newborn CCHD screening in practice: one was a pilot study at 2 hospitals in New York,34 and the other was a statewide study of birth hospitals in New Jersey.28 Both studies reported screening results during a short period and produced very different relative and absolute estimates of late-detected CCHD (25.0% vs 5.9% of newborns with CCHD) (Table 1).
As CCHD screening is more widely adopted, more precise estimation of its impact may be possible by reviewing actual clinical experiences for many years in multiple geographic areas. Until then, retrospective review of infants’ CCHD diagnostic experiences remains a relevant way to estimate the potential future effect of universal screening. The purpose of this study was to estimate the proportion of US infants with clinically validated, nonsyndromic, screening-detectable CCHD whose condition was detected late, defined as detection more than 3 days after birth, and to investigate clinical and demographic factors associated with late detection.
The National Birth Defects Prevention Study (NBDPS) is an ongoing, multisite, population-based case-control study conducted in 10 states (Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey [through 2002], New York, North Carolina [beginning 2003], Texas, and Utah [beginning 2003]) to investigate genetic and environmental risk factors for selected major structural birth defects.38 Population-based ascertainment of infants with birth defects at each study site ranges from entire states (Arkansas, Iowa, New Jersey, and Utah) to selected regions within states (California, Georgia, Massachusetts, New York, North Carolina, and Texas). New York was the only NBDPS site included in this analysis that relied on a combination of active and passive case ascertainment; all other study sites used active case ascertainment. For our purposes, active ascertainment means that trained staff culled multiple medical records to identify and extract pertinent phenotypic information. Infants with recognized or strongly suspected chromosomal abnormalities or single-gene conditions were excluded from the study. The NBDPS reports clinical information abstracted from maternal and infant medical records by birth defects surveillance programs at each study site. Inclusion criteria for congenital heart defects in the NBDPS require that the defects be confirmed by echocardiography, catheterization, surgery, or autopsy findings.39 The NBDPS gathers additional information on demographic characteristics, exposures (eg, nutritional, behavioral, or occupational) and medication use before and during pregnancy through telephone interviews with the mothers. Interviews are conducted in English or Spanish 6 weeks to 24 months after an infant’s estimated date of delivery (EDD). Approximately 63% of mothers of infants with congenital heart defects participated in the telephone interview. The NBDPS was approved by institutional review boards at the Centers for Disease Control and Prevention and all study sites.
In this analysis, we considered all live-born infants with congenital heart defects with an EDD from January 1, 1998, through December 31, 2007, and whose mothers were interviewed for the NBDPS. We excluded all infants born to mothers residing in New Jersey for all years and to mothers residing in Texas with an EDD before June 1998, because those study sites included only a sample of eligible infants with congenital heart defects in the NBDPS. The NBDPS methods for classifying congenital heart defects in infants have been described previously.39,40 Briefly, classification is based on the primary congenital heart defect by a team of clinicians with expertise in pediatric cardiology and clinical genetics.
For this study, we restricted our analysis to infants with CCHD potentially detectable by screening, defined as hypoplastic left heart syndrome, pulmonary atresia, dextrotransposition of the great arteries, truncus arteriosus, tricuspid atresia, tetralogy of Fallot, total anomalous pulmonary venous return, critical aortic stenosis, coarctation of the aorta, double-outlet right ventricle, Ebstein anomaly, interrupted aortic arch, critical pulmonary stenosis, and single ventricle.1 The first 7 conditions usually present with hypoxemia and are classified as primary screening targets.3 Infants with at least 1 screening-detectable CCHD condition were identified through the existing NBDPS heart classification system,39 with 2 exceptions. First, infants with congenital heart defects classified as multiple complex, other associations, unbalanced atrioventricular septal defects with or without outflow tract obstruction, or laterality defects underwent review by one of us (T.R.-C.) with expertise in pediatric cardiology and the NBDPS heart classification system to determine if 1 or more of the screening-detectable CCHD conditions was present. Second, infants with aortic or pulmonary stenosis were included only when the NBDPS clinical classifiers’ comments indicated that the infant underwent valvuloplasty or had critical or severe valve stenosis. Among infants with 1 screening-detectable CCHD, results are presented by individual CCHD type. Infants with more than 1 such condition (eg, coarctation of aorta and double-outlet right ventricle) are reported in a multiple CCHD category.
Based on abstracted medical record information, we identified the first date on which infants with CCHD underwent a diagnostic echocardiography (fetal or postnatal) or autopsy. Because CCHD screening is recommended to occur at 24 to 48 hours after birth,3 we classified CCHD detection as late if the infant did not have abstracted evidence of having received a diagnostic echocardiography prenatally or within 3 days of birth. We conservatively selected 3 days rather than 2 because the NBDPS does not capture time of birth; therefore, a cutoff of 2 days might erroneously identify infants as having late CCHD detection when a diagnosis was made within 48 hours. Every infant who received a first diagnosis at autopsy could reasonably be considered to have late detection of CCHD. However, we excluded infants with a diagnosis at autopsy within 3 days of birth because we aimed to quantify the proportion of infants with CCHD who might benefit from proposed universal screening, and such infants might not have the chance to undergo screening. We also excluded infants who did not have a recorded echocardiography. Such infants were assumed to have incomplete records in the NBDPS because interventions (ie, cardiac catheterization or surgery) are usually preceded by or accompanied by imaging studies. We restricted the analysis to infants with CCHD diagnosis by echocardiography performed within 1 year of age.1
We first assessed the timing of infants’ CCHD diagnosis (prenatal, postnatal, or at autopsy) through descriptive statistics by calculating frequencies and their corresponding 95% Wald CIs. We used exact 95% CIs for cell counts less than 10. We then estimated crude and adjusted prevalence ratios (PRs) and corresponding 95% CIs for late detection based on selected infant and maternal demographic and clinical characteristics in Poisson regression models with robust sandwich error variance.41,42 We assessed the following characteristics from information abstracted from birth defects surveillance data: NBDPS study site, the presence of extracardiac defects (ie, major defects in organ systems outside of the heart),39 CCHD type, gestational age at delivery, and EDD year. We assessed the following characteristics from information reported during the NBDPS maternal interview: first-degree family history of congenital heart defects, plurality, and maternal characteristics, including race/ethnicity, age at delivery, education, diabetes mellitus before or during the index pregnancy, prepregnancy body mass index, hypertension before or during the pregnancy, fertility treatments, previous pregnancy losses, and trimester of the first prenatal care visit. The analysis was conducted using commercially available statistical software (SAS, version 9.2; SAS Institute, Inc).
Of 9441 infants with nonsyndromic congenital heart defects and a 1998-2007 EDD whose mothers participated in an NBDPS interview, 3746 were included in the analysis (Figure). Of these, 1106 (29.5% [95% CI, 28.1%-31.0%]) underwent diagnosis through echocardiography more than 3 days after birth (Table 2). For 6 infants (0.2% [95% CI, 0.1%-0.4%]), CCHD diagnosis occurred at autopsy more than 3 days after birth (Table 2). Late detection by CCHD type ranged from 9 of 120 infants (7.5% [95% CI, 3.5%-13.8%]) with pulmonary atresia to 497 of 801 (62.0% [58.7%-65.4%]) with coarctation of the aorta (Table 2). The frequency of late detection varied within CCHD types by the presence or absence of extracardiac defects and by NBDPS study site (Supplement [eFigures 1 and 2]). For 542 infants (14.5% [95% CI, 13.3%-15.6%]), the first echocardiogram documented in the abstracted medical record was prenatal. Among infants with late-detected CCHD diagnosed through echocardiography (n = 1100), the median time from birth to diagnosis was 14 (range, 4-363; interquartile range [IQR], 7-48) days (Table 2). Among the 6 infants who received the initial diagnosis at autopsy more than 3 days after birth (n = 6), the median time from birth to diagnosis was 5 (range, 4-21; IQR, 4-11) days (data not shown).
When we controlled for all demographic and clinical factors under consideration, the prevalence of late detection among infants with CCHD varied significantly by the presence of extracardiac defects, CCHD type, and NBDPS study site (Table 3). Quiz Ref IDThe estimated adjusted prevalence of late detection among infants with extracardiac defects was 42% less (adjusted PR, 0.58 [95% CI, 0.49-0.69]) than the adjusted prevalence in infants without extracardiac defects (Table 3). The estimated adjusted prevalence of late detection among infants with Ebstein anomaly, single ventricle, critical pulmonary stenosis, interrupted aortic arch, tetralogy of Fallot, double-outlet right ventricle, truncus arteriosus, total anomalous pulmonary venous return, and coarctation of the aorta were each significantly greater than the adjusted prevalence among infants with hypoplastic left heart syndrome (the reference group). Late detection varied significantly by NBDPS study site, with a 2-fold difference between the sites with the lowest and highest adjusted prevalence of late detection (adjusted PR, 2.09 [95% CI, 1.66-2.63]) (Table 3).
Quiz Ref IDBased on data from the NBDPS, we estimated that the diagnosis of nonsyndromic CCHD occurred more than 3 days after birth in 29.5% of infants, including fewer than 1% with the initial diagnosis at autopsy. These infants, therefore, might have benefited from universal screening through pulse oximetry at their birth hospitals. Infants with extracardiac defects were significantly less likely to have late detection, and late detection varied by CCHD type and NBDPS study site.
Our study focused explicitly on the potential effect of new US recommendations for CCHD screening using multisite data and examined the diagnostic experience of infants with CCHD during the entire first year of life. Our estimate is similar to that of a retrospective study at an NBDPS contributing site—metropolitan Atlanta—that estimated that 31.3% of infants with CCHD did not receive a diagnosis on their day of birth.31 Other retrospective US studies with substantially lower estimated proportions of infants with late detection of CCHD (ie, 4%-7%)32,35 examined fewer CCHD types than our study or identified late detection of CCHD only through the occurrence of death.33,35 However, estimates from most previous studies of late CCHD detection28- 30,32- 35 (Table 1) appear to have included infants with genetic disorders, whereas our study excluded such infants. Most previous studies29,30,32,35 used exclusively administrative coding to identify CCHD diagnoses, which might inaccurately classify heart defects or fail to capture whether a defect such as aortic stenosis or pulmonary stenosis is critical.36,37 Previous studies of late CCHD detection also used different data sources—such as hospital admission records with or without accompanying statewide death records—to identify infants with late detection of CCHD. One previous study30 ascertained infants with late detection of CCHD less than 1 month after birth. Finally, previous studies were limited to 2 hospitals,34 a single metropolitan area,31,35 or a single state.28- 30,32,33
In our study, the prevalence of late detection varied widely (from 7.5% to 62.0%) by CCHD type. Evidence suggests that the sensitivity of CCHD screening through pulse oximetry also may vary substantially by CCHD type—a proxy for the presence of hypoxemia. A recent meta-analysis2 reported that pulse oximetry conducted at least 24 hours after birth was 78% sensitive to detect CCHD overall. However, a review of 13 screening studies43 (with 258 809 infants undergoing screening, of whom 256 were ultimately diagnosed as having CCHD) from 1998 through 2009 reported sensitivities ranging from 36% (95% CI, 24%-50%) for coarctation of the aorta and interrupted aortic arch (18 of 50 infants) to 100% (95% CI, 44%-100%) for single ventricle (6 of 6 infants), double-outlet right ventricle (5 of 5 infants), and pulmonary atresia with intact septum (3 of 3 infants). Screening-detectable CCHD constitutes a heterogeneous group of rare congenital heart defects, and the numbers of infants included in these CCHD defect–specific estimates are very small. The high rate of late detection among infants with coarctation of the aorta (62.0%) in our study influenced our overall estimate of 29.5% late detection; excluding these infants would result in an overall estimate of late detection in 609 of 2945 (20.7% [95% CI, 19.2%-22.2%]). Nonhypoxemic cases of coarctation of the aorta (ie, not detectable through screening) likely contributed to our estimated prevalence of late detection for that condition. Unfortunately, we were unable to ascertain lesion severity.
Infants with extracardiac defects were less likely to have late detection of CCHD in our study. Infants with birth defects affecting multiple organ systems may receive additional medical attention prenatally or at birth, which might explain why late detection was significantly lower among such infants. The proportion of infants in our study with nonsyndromic extracardiac defects (17.0% [95% CI, 15.8%-18.2%]) was similar to those of other population-based studies of infants and children with congenital heart defects.44,45 However, because the NBDPS excludes infants with genetic syndromes, our study might have estimated a higher proportion of late detection than actually exists in the population. Our results also indicated that late CCHD detection varied significantly among the 9 NBDPS study sites included in this analysis. This variation may reflect, in part, nonuniformity in neonatal clinical practice, which cannot be addressed using existing birth defects surveillance data in the NBDPS. In addition, the NBDPS sites draw from different populations in terms of socioeconomic status, urbanicity, and geographic region; thus, inference about the underlying meaning of the observed study site variability would require further investigation.
We found no significant temporal trend in terms of increasing or decreasing prevalence of late CCHD detection during the study period (Table 2). Recent studies46- 49 have reported inconsistent findings about whether race/ethnicity is associated with outcomes such as mortality and hospital readmission among infants with congenital heart defects, although no significant racial/ethnic associations were observed in this analysis. We found no significant association between the timing of the first prenatal care visit and timely CCHD detection; however, this variable is a limited indicator of the experience of prenatal care.
This study has a number of limitations. The NBDPS does not explicitly seek information on the initial diagnosis of congenital heart defects, but instead a diagnosis by specific means (echocardiography, autopsy, catheterization, or surgery). Therefore, we may have overestimated the proportion of infants with late CCHD detection owing to missing information on initial diagnoses. However, echocardiography is recommended to diagnose CCHD, even if an infant receives a definitive diagnosis through other means.3,50 Missing or erroneous examination information might vary by NBDPS site because ascertainment of follow-up records (ie, outpatient echocardiography) is not standardized. Another limitation is that we restricted our analysis to infants in the NBDPS whose mothers were interviewed. Because infants of noninterviewed mothers did not undergo classification by NBDPS clinicians, we were unable to compare the 2 groups. A related limitation is that many of the factors we assessed were based on mothers’ self-reported demographic and clinical information (ie, timing of entry into prenatal care, diabetes mellitus status, and prepregnancy body mass index).
Our study has 3 notable strengths that distinguish it from previous US studies. First, we used data compiled from multiple population-based birth defects surveillance programs that included infants with clinically validated CCHD diagnoses.51 Second, because we used abstracted medical records to identify and classify infants according to CCHD type, we likely have achieved greater clinical accuracy than previous studies that relied exclusively on administrative data to classify CCHD diagnoses. Third, we used clinical definitions of CCHD and timely detection that are directly pertinent to new US federal recommendations for universal newborn screening for CCHD through pulse oximetry.
We estimate that 29.5% of live-born infants with nonsyndromic CCHD in the NBDPS received the diagnosis more than 3 days after birth. The proportions of infants with late CCHD detection varied substantially by CCHD type, from 7.5% (pulmonary atresia) to 62.0% (coarctation of the aorta). These results suggest that many infants with CCHD might benefit from screening through pulse oximetry before birth hospital discharge. Whether such infants are detected through screening is likely to vary by a number of factors, including CCHD type and the presence of extracardiac defects. Additional population-based studies of universal screening in practice are needed.
Accepted for Publication: October 20, 2013.
Corresponding Author: Cora Peterson, PhD, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Mailstop F-62, 4770 Buford Hwy, Atlanta, GA 30341 (firstname.lastname@example.org).
Published Online: February 3, 2014. doi:10.1001/jamapediatrics.2013.4779.
Author Contributions: Drs Peterson and Ailes contributed equally to this study. Drs Peterson and Ailes had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Peterson, Ailes, Gilboa.
Acquisition of data: Peterson.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Peterson.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Ailes, Gilboa.
Administrative, technical, or material support: All authors.
Study supervision: Gilboa.
Conflict of Interest Disclosures: None reported.
Funding/Support: This study was supported by cooperative agreements under PA 96043, PA 02081 and FOA DD09-001 from the Centers for Disease Control and Prevention (CDC).
Role of the Sponsor: The funding source designed the protocol for the original data collection and approved authors’ protocol for this study. The funding source had no role in the design and conduct of the study; analysis or interpretation of the data; and preparation of the manuscript. The CDC and the California Department of Public Health reviewed the manuscript and approved submission for publication.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or the California Department of Public Health.
Additional Contributions: We thank the participating families, staff, and scientists who contribute to the National Birth Defects Prevention Study. We thank the Maternal, Child, and Adolescent Health Program of the California Department of Public Health for providing data on study subjects for the National Birth Defects Prevention Study.